Metrics as of 10/14/2026, 08:36 AM (Berlin time), refresh in progress.
Cytokinetics Stock
Cytokinetics, Incorporated
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert I. Blum
- Employees
- 673
- Market cap
- $8.6 B
- IPO
- 26/04/2004
Cytokinetics, Incorporated is a biopharmaceutical company within the Healthcare sector, headquartered in South San Francisco, USA. Founded in 1997, the company focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Cytokinetics stock: price history
1D
-3.1%
1W
-1.5%
1M
-10.7%
6M
-7.1%
YTD
-2.5%
1Y
+5.1%
2Y
+12.1%
5Y
+67.9%
10Y
+577.8%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~9% weaker price swings than usual
Ask the agents about Cytokinetics
Analyst assessment of Cytokinetics
PRICE TARGET LOW
US$103.00
CONSENSUS
US$113.33
MEDIAN
US$112.00
PRICE TARGET HIGH
US$140.00
0
STRONG BUY
34
BUY
1
HOLD
0
SELL
0
STRONG SELL
35
TOTAL · Buy
As of: 08/10/2026
Cytokinetics stock metrics
P/E
-8.59
P/B
-47.17
EV/EBITDA
-10.57
RETURN ON EQUITY
114.6%
NET MARGIN
-622.8%
DEBT/EQUITY
-7.32
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.8%
FLOAT SHARES
119,238,171
AVG. DAILY VOLUME (30D)
2,091,935
Insider transactions (SEC)
Blum Robert I
Blum Robert I
Malik Fady Ibraham
Malik Fady Ibraham
Blum Robert I
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.1%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cytokinetics stock
What does Cytokinetics do?
Cytokinetics, Incorporated is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert I. Blum, the company employs around 673 people.
The IPO was on 26/04/2004; the stock trades on NASDAQ under the ticker CYTK.
What do analysts say about Cytokinetics stock?
35 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$113.33, ranging from US$103.00 to US$140.00, with a median of US$112.00.
This is an external assessment, not a statement by Market Jury.
When does Cytokinetics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -9% stronger than usual.
Does Cytokinetics pay a dividend?
No, Cytokinetics currently does not pay a dividend.
Which stocks are comparable to Cytokinetics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cytokinetics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cytokinetics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.